|Articles|June 4, 2003

Experimental Lab Test for SARS Made Available to 100 Labs Nationwide

WASHINGTON, D.C. -- The Centers for Disease Control and Prevention (CDC) is offering a new experimental laboratory test for patients suspected of being infected with the SARS virus to about 100 specialized laboratories around the country.

The experimental diagnostic test was rapidly developed by the CDC during the past few months in an urgent effort to address this pressing public health need. The Food and Drug Administration (FDA) has worked closely with the CDC to develop appropriate information for patients and health professionals in order to make the test available on an investigational basis. Because information about the test's performance is still being collected, patients will be asked for written consent before the test is used.

"Because of the special efforts of the dedicated professionals at these two agencies to respond effectively to SARS, we now have a needed SARS diagnostic test for use at a growing number of laboratories," Health and Human Services Secretary Tommy G. Thompson said. "This experimental test marks a significant step forward in our ability to confront and ultimately overcome this new disease, and its development embodies the commitment of our department to protecting public health."

The new test uses polymerase chain reaction technology to detect evidence of the presence of the coronavirus. Polymerase chain reaction is a way to detect the genetic material of an organism in a couple of hours. The standard method of growing the organism in cell culture takes several days or up to several weeks.

As part of the wider distribution of the new test, patients and practitioners will receive clear information about how the test may assist in diagnosing SARS. The CDC and FDA are also cooperating on further scientific evaluation of the new test's accuracy and reliability.

In addition, through the evaluation of the test in more patients and settings, more will be learned about the accuracy and reliability of the test, and how it can be improved. This information will support the development of approved diagnostic tests as quickly as possible.

Source: CDC


Related to this article

Infection preventionists in full PPE with children in DRC.  (Image credit: author with AI)
Nearly 4 months into the DRC's Bundibugyo virus disease outbreak, some indicators suggest transmission may be slowing. But shifting hotspots, treatment-center capacity problems, community deaths, and incomplete surveillance data show why national case totals alone cannot determine whether containment has been achieved.
Health care workers from the US speaking with other health care workers in DRC.  (Image credit: author with AI)
Is the Ebola outbreak in the DRC getting better? The answer depends on which numbers you examine. Several important indicators are moving in the right direction, including slower case growth and a declining Rₜ. But major gaps remain in contact tracing, testing, community deaths, safe burial coverage, and treatment capacity in some of the hardest-hit areas. ICT takes a deeper look at the latest outbreak data and why the numbers suggest cautious optimism, not victory.
Dyan Troxell, MSN, RN, director of clinical education at HandCraft Linen Services; J.J. Odom, MBA, CHESP, CMIP, T-CHEST, university director of buildings and grounds for UConn Health and chair-elect of the AHE Board; and Jenna Rivers, MPH, CPH, CIC, manager of infection prevention and control at Moffitt Cancer Center in Tampa, Florida.
At AHE Exchange 2026, ICT spoke with experts representing commercial laundry services, EVS, and infection prevention about the systems behind a successful reusable linen program. They discuss linen quality, reject rates, unnecessary waste, frontline education, data, PAR levels, infection prevention oversight, and why strong relationships between health care facilities and their laundry providers matter.
A group of students raising their hands in class during a lecture  (Adobe Stock 292282454 by Mediteraneo
How do you celebrate an infection that never happened? That's one of the unusual challenges infection preventionists share with teachers. Both can spend their careers changing outcomes they may never see. Both educate people who don't always want to listen. Both are second-guessed. Both face burnout. And both must somehow keep remembering why they started.